Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

EXCLUSIVE - When Richard Nelson had his shock bowel cancer diagnosis he was offered a new innovative 'vaccine' clinical trial ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...